Benjamin Ribba

Title: Benjamin Ribba: Innovator in Therapeutic Dosage Regimens

Introduction

Benjamin Ribba is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of therapeutic agents, particularly in the design of dosage regimens. His work focuses on optimizing treatment protocols for individuals receiving IL-2 receptor-targeted therapies.

Latest Patents

Ribba holds a patent for "Materials and methods relating to dosage regimen design." This invention provides materials and methods for determining optimal dosage regimens for therapeutic agents. Specifically, it relates to dosage regimens for therapeutic agents capable of targeting the IL-2 receptor, preferably interleukin 2 (IL2)-based therapeutic agents. The methods outlined in his patent allow for the determination of general dosage regimens for new IL-2R targeted therapeutic agents, as well as the creation of specifically tailored dosage regimens for individuals undergoing treatment.

Career Highlights

Benjamin Ribba is associated with Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His work at the company has allowed him to contribute to advancements in therapeutic methodologies and patient care.

Collaborations

Ribba has collaborated with notable colleagues such as Hans Peter Grimm and Volker Teichgräaeber. These collaborations have further enhanced the impact of his work in the field of therapeutic agents.

Conclusion

Benjamin Ribba's innovative approach to dosage regimen design has the potential to significantly improve therapeutic outcomes for patients. His contributions to the field exemplify the importance of tailored treatment strategies in modern medicine.